Patricia Mendez

Patricia Mendez

Auto-generated profile, based on publicly available information

Patricia Mendez

Gilead Sciences , Warren, New Jersey , USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2022 in Journal of Hepatology
Verified
Journal Article
Open access
AGAdam J. Gehring
Adam J. Gehring
PMPatricia Mendez
Patricia Mendez
KRKirsten Richter
Kirsten Richter
HEHildegund C. J. Ertl
Hildegund C. J. Ertl
EDEric Donaldson
Eric Donaldson
VMVeronica Miller
Veronica Miller
There have been unprecedented advances in the identification of new treatment targets for chronic hepatitis B that are being developed with the goal of achieving functional cure in patients who would otherwise require lifelong nucleoside analogue treatment. Many of the new investigational therapies either directly target the immune system or are anticipated to impact immunity indirectly through modulation of the viral lifecycle and antigen production. While new viral biomarkers (HBV RNA, HBcAg, small, middle, large HBs isoforms) are proceeding through validation steps in clinical studies, immunological biomarkers are non-existent outside of clinical assays for antibodies to HBs, HBc and HBe. To develop clinically applicable immunological biomarkers to measure mechanisms of action, inform logical combination strategies, and guide clinical management for use and discontinuation of immune-targeting drugs, immune assays must be incorporated into phase I/II clinical trials. This paper will discuss the importance of sample collection, the assays available for immunological analyses, their advantages/disadvantages and suggestions for their implementation in clinical trials. Careful consideration must be given to ensure appropriate immunological studies are included as a primary component of the trial with deeper immunological analysis provided by ancillary studies. Standardising immunological assays and data obtained from clinical trials will identify biomarkers that can be deployed in the clinic, independently of specialised immunology laboratories.

26 August 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MPMarion G Peters
Marion G Peters
MYMan-Fung Yuen
Man-Fung Yuen
NTNorah Terrault
Norah Terrault
JFJohn Fry
John Fry
PLPietro Lampertico
Pietro Lampertico
OLOliver Lenz
Oliver Lenz
Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.

18 December 2015 in Liver International
Verified
Journal Article
Closed access
PDF file
JKJia-Horng Kao
Jia-Horng Kao
DJDonald M. Jensen
Donald M. Jensen
MMMichael Manns
Michael Manns
IJIra Jacobson
Ira Jacobson
HKHiromitsu Kumada
Hiromitsu Kumada
SNStephanie Noviello
Stephanie Noviello